Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

Najat Khan: Good morning, and thank you so much for joining us. I want to start by briefly framing where Recursion Pharmaceuticals, Inc. is today in its journey and evolution. Over the past decade, ...

The pace of AI continues to be staggering. From simple pattern recognition systems to large language models (LLMs), and now as we move into the physical AI reality, the power of these systems ...

Abstract: In high-performance processor design, maintaining Return-Address Stack (RAS) integrity is crucial for efficient instruction flow. Yet, separating multi-level branch predictors from ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst ...

Visualize recursion in real-time — watch the call stack grow & shrink with stack and tree views. Built with HTML, CSS, JS (Canvas).